RxDoctor Payments Data

Brian Galofaro, MD

Family Medicine · Covington, LANPI 1629298278

Payments from drug & device makers

$7,706in general payments, 2019–2025

Across 516 payments — averaging $14.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$844
  • Pfizer$579
  • Lilly USA, LLC$553
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$451
  • Astellas Pharma US Inc$438
  • plus $4K from 35 others

What the payments were for

  • Food & beverage$7,61899%
  • Education$881%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,706 in reported general payments places this provider in the 85th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$67,657
Medicare patients
407
Services billed
1,375

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide48$56,805
JardianceEmpagliflozin24$34,190
ProliaDenosumab19$33,310
OzempicSemaglutide21$24,959
TrulicityDulaglutide12$23,071
JanuviaSitagliptin Phosphate19$17,410
VascepaIcosapent Ethyl15$9,840
SynthroidLevothyroxine Sodium15$1,245
Memantine Hcl27$1,115
Pregabalin71$970
Rosuvastatin Calcium65$752
Valsartan28$694
Testosterone Cypionate29$654
Pantoprazole Sodium54$607
Duloxetine Hcl28$549

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$553$79,87660 claims
Boehringer IngelheimJardiance$318$34,19024 claims
AmgenProlia$383$33,31019 claims
Novo NordiskOzempic$844$24,95921 claims
MerckJanuvia$120$17,41019 claims
AbbVieSynthroid$1,120$1,24515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Covington

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →